University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Hala Borno, MD

Hala Borno, MD

Assistant Clinical Professor, Division of Hematology/Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

Dr. Hala Borno is a medical oncologist specializing in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. She cares for patients at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). Her academic interests include cancer disparities and digital health technologies that improve clinical trial participation. Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics. She is now faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology. At HDFCCC, she is a member of the cancer committee, quality council, cancer control program, and prostate program. She is also a member of the American Society of Clinical Oncology and health disparities committee for Alliance for Clinical Trials in Oncology.

Education

University of North Carolina at Chapel Hill, B.S., 05/2008, Biochemistry
University of North Carolina at Chapel Hill, M.D., 05/2013, Medicine
University of California, San Francisco, Intern, 06/2014, Internal Medicine
University of California, San Francisco, Resident, 06/2016, Internal Medicine


Professional Experience

  • 2016-2018
    ACGME Fellow, Division of Hematology/Oncology, UCSF
  • 2017-2018
    Chief Fellow, Division of Hematology/Oncology, UCSF
  • 2018-present
    Assistant Clinical Professor, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 2009
    Foreign Language Area Studies Fellowship
  • 2011-2012
    Furlow Fund Global Health Research Fellowship, University of North Carolina at Chapel Hill
  • 2009-2013
    Medical Alumni Loyalty Fund Scholarship
  • 2013
    Arnold P. Gold Foundation
  • 2013
    Daniel T. Young Peace and Social Justice Award
  • 2017-present
    Geriatrics T32 NIH Grant
  • 2017-present
    Inside Out Accelerator Grant from the Clinical Innovation Center

Selected Publications

  1. Hala T. Borno; Daphne Y. Lichtensztajn; Scarlett L. Gomez; Nynikka R. Palmer; and Charles J. Ryan. Differential Use of Medical Versus Surgical Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer. CANCER. 2018; 0(0):0.
    View on PubMed
  2. Borno HT, Lichtensztajn DY, Gomez SL, Palmer NR, Ryan CJ. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. Cancer. 2018 Nov 16.
    View on PubMed
  3. Hala T. Borno, Eric J. Small. Apalutamide and its use in the treatment of prostate cancer. Future Oncology. 2018; 0(0):0.
    View on PubMed
  4. Borno HT, Small EJ. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2018 Nov 14.
    View on PubMed
  5. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemp Clin Trials Commun. 2018 Dec; 12:60-67.
    View on PubMed
  6. Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, Joseph G, Allen IE, Venook AP, Altschuler A, Dhruva A. Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers. PLoS One. 2018; 13(7):e0199423.
    View on PubMed
  7. Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ. At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials. Oncologist. 2018 Apr 26.
    View on PubMed
  8. Hala T. Borno, Janet E. Cowan, Shoujun Zhao, Peter Carroll, Charles J. Ryan. CaPSURE update: Examining primary treatment and survival among men with prostate cancer and bony metastatic disease. 2018.
    View on PubMed
  9. Hala T Borno, Joseph P. McGuire, Ann C. Griffin, Charles J. Ryan, Celia Kaplan, Eric Jay Small. Journal of Clinical Oncology. Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center. 2018; 36(6_suppl ):267-267.
    View on PubMed
  10. Borno H. Blood and conflict: managing bleeding disorders in Gaza. East Mediterr Health J. 2018 Jan 02; 23(11):786-787.
    View on PubMed
  11. Natalini J, Borno H, Jin L, Jensen T. An unusual manifestation of diabetic ketoacidosis and acute colonic pseudo-obstruction. The Royal Society of Medicine Journals. 2017; 8(6).
    View on PubMed
  12. Borno H, Siegel A, Ryan C. The problem of representativeness of clinical trial participants: understanding the role of hidden costs. J Health Serv Res Policy. 2016 Jul; 21(3):145-6.
    View on PubMed
  13. Borno HT, Hussein EA, Dudin A, van Aalst JA. Incidence of cleft lip and palate in the palestinian territories: a retrospective study from the Makassed Hospital neonatal unit. Cleft Palate Craniofac J. 2014 Jul; 51(4):472-5.
    View on PubMed
  14. Hussein E, Borno HT, van Aalst JA. Cleft Lip and Palate Diagnosis and Management. Birthing and Building Nascent Cleft Teams in Developing Countries. 2012; 871-877.
    View on PubMed

Go to UCSF Profiles, powered by CTSI